Evidence map›Paper›PMID 23902433›Full record

ArticleBMC bioinformatics2013

Parallel comparison of Illumina RNA-Seq and Affymetrix microarray platforms on transcriptomic profiles generated from 5-aza-deoxy-cytidine treated HT-29 colon cancer cells and simulated datasets.

Xiao Xu, Yuanhao Zhang, Jennie Williams, Eric Antoniou, W Richard McCombie, Song Wu, Wei Zhu, Nicholas O Davidson, Paula Denoya, Ellen Li

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC bioinformatics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 148 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Xiao XuSchool of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
Yuanhao Zhang
Jennie Williams
Eric Antoniou
W Richard McCombie
Song Wu
Wei Zhu
Nicholas O Davidson
Paula Denoya
Ellen Li
Stony Brook University · USCold Spring Harbor Laboratory · USWashington University in St. Louis · US

Funding

Single-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI John Edward Moses · 1987 to 2026
$118.9M
Washington University DDRCC Supplemental Equipment RequestP30DK052574 · NIDDK · WASHINGTON UNIVERSITY · PI Nicholas O. Davidson · 2000 to 2026
$30.8M
HEPATIC SYNTHESIS AND SECRETION OF APOLIPOPROTEIN (A)R01DK056260 · NIDDK · WASHINGTON UNIVERSITY · PI DAVIDSON, NICHOLAS O. · 1999 to 2017
$5.9M
ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESISR01HL038180 · NHLBI · WASHINGTON UNIVERSITY · PI DAVIDSON, NICHOLAS O. · 1986 to 2018
$3.8M
Phosphosulindac, miRNAs and cancer racial disparityR01CA140487 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI WILLIAMS, JENNIE L · 2010 to 2014
$1.6M
NCI NIH HHS CA045508NCI NIH HHS R01 CA140487NCI NIH HHS R01CA140487NHLBI NIH HHS R01HL-38180NIDDK NIH HHS P30DK-52574NIDDK NIH HHS R01DK-56260
6 · The paper itself

Abstract

backgroundHigh throughput parallel sequencing, RNA-Seq, has recently emerged as an appealing alternative to microarray in identifying differentially expressed genes (DEG) between biological groups. However, there still exists considerable discrepancy on gene expression measurements and DEG results between the two platforms. The objective of this study was to compare parallel paired-end RNA-Seq and microarray data generated on 5-azadeoxy-cytidine (5-Aza) treated HT-29 colon cancer cells with an additional simulation study.

methodsWe first performed general correlation analysis comparing gene expression profiles on both platforms. An Errors-In-Variables (EIV) regression model was subsequently applied to assess proportional and fixed biases between the two technologies. Then several existing algorithms, designed for DEG identification in RNA-Seq and microarray data, were applied to compare the cross-platform overlaps with respect to DEG lists, which were further validated using qRT-PCR assays on selected genes. Functional analyses were subsequently conducted using Ingenuity Pathway Analysis (IPA).

resultsPearson and Spearman correlation coefficients between the RNA-Seq and microarray data each exceeded 0.80, with 66%~68% overlap of genes on both platforms. The EIV regression model indicated the existence of both fixed and proportional biases between the two platforms. The DESeq and baySeq algorithms (RNA-Seq) and the SAM and eBayes algorithms (microarray) achieved the highest cross-platform overlap rate in DEG results from both experimental and simulated datasets. DESeq method exhibited a better control on the false discovery rate than baySeq on the simulated dataset although it performed slightly inferior to baySeq in the sensitivity test. RNA-Seq and qRT-PCR, but not microarray data, confirmed the expected reversal of SPARC gene suppression after treating HT-29 cells with 5-Aza. Thirty-three IPA canonical pathways were identified by both microarray and RNA-Seq data, 152 pathways by RNA-Seq data only, and none by microarray data only.

conclusionsThese results suggest that RNA-Seq has advantages over microarray in identification of DEGs with the most consistent results generated from DESeq and SAM methods. The EIV regression model reveals both fixed and proportional biases between RNA-Seq and microarray. This may explain in part the lower cross-platform overlap in DEG lists compared to those in detectable genes.

Indexed as

AlgorithmsAzacitidineColonic NeoplasmsGene Expression ProfilingHT29 CellsHumansOligonucleotide Array Sequence AnalysisRegression AnalysisRNA, NeoplasmSensitivity and SpecificitySequence Analysis, RNAAzacitidineRNA, Neoplasm

Identifiers

PMID23902433
PMCPMC3697991
OpenAlexW2017558877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.